Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.

about

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.

P2860

Q33429115-A0AC03D5-B0A9-4152-A2CC-E6CCC3CEA754

P2860

Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.

Item

http://www.wikidata.org/entity/Q38253354

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Arsenic trioxide-based therapy ...... nalysis and systematic review.

@en

type

Item

label

Arsenic trioxide-based therapy ...... nalysis and systematic review.

@en

prefLabel

Arsenic trioxide-based therapy ...... nalysis and systematic review.

@en

P1476

Arsenic trioxide-based therapy ...... nalysis and systematic review.

@en

P2093

Bing Liu

http://www.w3.org/2001/XMLSchema#string

Fang Wang

http://www.w3.org/2001/XMLSchema#string

Huiren Chen

http://www.w3.org/2001/XMLSchema#string

Jinxing Lou

http://www.w3.org/2001/XMLSchema#string

Kai Yang

http://www.w3.org/2001/XMLSchema#string

Peng Chen

http://www.w3.org/2001/XMLSchema#string

Xiaodong Liu

http://www.w3.org/2001/XMLSchema#string

Xuepeng He

http://www.w3.org/2001/XMLSchema#string

Yuan Zhang

http://www.w3.org/2001/XMLSchema#string

Zhi Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia

Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

NF-kappa B as a therapeutic target in multiple myeloma.

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.

P304

1593-1599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/OTT.S67165

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25246802

http://www.w3.org/2001/XMLSchema#string

P932

4166211

http://www.w3.org/2001/XMLSchema#string

Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.

about

P2860

P2860

Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932